ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacituzumab tirumotecan

Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.

Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 3, 202350 company-led studies, 48 open or runningLicense: Kelun-Biotech → MerckNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only2928 open or runningphase 3since Oct 3, 2023Apr 1, 2022May 10, 2027phase 3 · NCT06074588
Sichuan Kelun Pharmaceuticalits history only1716 open or runningphase 3since Apr 15, 2022Apr 15, 2022Nov 2026phase 3 · NCT06448312
Klus Pharma33 open or runningphase 2since Oct 29, 2019Oct 29, 2019Nov 30, 2027phase 2 · NCT05642780
Convalife (Shanghai)its history only11 open or runningphase 2since Aug 22, 2025Aug 22, 2025Aug 12, 2028phase 2 · NCT07157956
  • Named in Merck’s own pipeline as sacituzumab tirumotecan (MK-2870), phase 4, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.

History and studies of Klus Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2019First study: phase 2 study in Carcinoma, Ovarian EpithelialFirst studyNCT04152499 · 1,410 enrolled · United States, Canada, Chile and more
  2. Nov 30, 2022Phase 2 study in Solid TumorNCT05642780 · 240 enrolled · United States, Australia, Belgium and more
  3. Apr 3, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05816252 · 356 enrolled · China, Georgia, Romania and more
  4. Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264

Ahead

  1. Nov 30, 2027Primary completion: phase 2 study in Solid TumorNCT05642780

TargetBeta

“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 3 Klus Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05816252Carcinoma, Non-Small-Cell Lung · China, Georgia, Romania and more2Active, not recruitingAug 31, 2026356
NCT05642780Solid Tumor · United States, Australia, Belgium and more2Active, not recruitingNov 30, 2027240
NCT04152499Carcinoma, Ovarian Epithelial · United States, Canada, Chile and more2Active, not recruitingNov 30, 20251,410

How it is read

Names in the registry

  • “Sacituzumab tirumotecan”, 22 entries
  • “SKB264”, 15 entries
  • “Sacituzumab Tirumotecan”, 5 entries
  • “SKB264+SKB118”, 2 entries
  • “sac-TMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.